Corcept Therapeutics (CORT) Competitors

$57.08 +5.92 (+11.57%)

Closing price 05/13/2026 04:00 PM Eastern

Extended Trading

$58.14 +1.06 (+1.86%)

As of 05:08 AM Eastern

CORT vs. ANVS, JAZZ, SUPN, NKTR, and PRGO

Should you buy Corcept Therapeutics stock or one of its competitors? MarketBeat compares Corcept Therapeutics with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Corcept Therapeutics include Annovis Bio (ANVS), Jazz Pharmaceuticals (JAZZ), Supernus Pharmaceuticals (SUPN), Nektar Therapeutics (NKTR), and Perrigo (PRGO). These companies are all part of the "medical" sector.

How does Corcept Therapeutics compare to Annovis Bio?

Corcept Therapeutics (NASDAQ:CORT) and Annovis Bio (NYSE:ANVS) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Corcept Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Annovis Bio has a beta of 1.26, meaning that its share price is 26% more volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Annovis Bio. Annovis Bio is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	8.05	$99.65M	$0.35	163.09
Annovis Bio	N/A	N/A	-$28.85M	-$1.40	N/A

Corcept Therapeutics currently has a consensus target price of $70.83, suggesting a potential upside of 24.09%. Annovis Bio has a consensus target price of $13.50, suggesting a potential upside of 507.29%. Given Annovis Bio's higher possible upside, analysts plainly believe Annovis Bio is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Annovis Bio	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25

In the previous week, Corcept Therapeutics had 7 more articles in the media than Annovis Bio. MarketBeat recorded 8 mentions for Corcept Therapeutics and 1 mentions for Annovis Bio. Corcept Therapeutics' average media sentiment score of 0.72 beat Annovis Bio's score of 0.00 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Annovis Bio	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 15.8% of Annovis Bio shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 20.8% of Annovis Bio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics has a net margin of 6.14% compared to Annovis Bio's net margin of 0.00%. Corcept Therapeutics' return on equity of 7.40% beat Annovis Bio's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Annovis Bio	N/A	-159.43%	-133.49%

Summary

Corcept Therapeutics beats Annovis Bio on 13 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Corcept Therapeutics (NASDAQ:CORT) and Jazz Pharmaceuticals (NASDAQ:JAZZ) are both medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their analyst recommendations, valuation, institutional ownership, dividends, earnings, profitability, media sentiment and risk.

Corcept Therapeutics has a beta of 0.36, meaning that its share price is 64% less volatile than the broader market. Comparatively, Jazz Pharmaceuticals has a beta of 0.27, meaning that its share price is 73% less volatile than the broader market.

In the previous week, Corcept Therapeutics and Corcept Therapeutics both had 8 articles in the media. Corcept Therapeutics' average media sentiment score of 0.72 beat Jazz Pharmaceuticals' score of 0.49 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Jazz Pharmaceuticals	1 Very Positive mention(s)	0 Positive mention(s)	5 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Corcept Therapeutics currently has a consensus target price of $70.83, suggesting a potential upside of 24.09%. Jazz Pharmaceuticals has a consensus target price of $230.56, suggesting a potential downside of 0.76%. Given Corcept Therapeutics' higher possible upside, analysts plainly believe Corcept Therapeutics is more favorable than Jazz Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Jazz Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	14 Buy rating(s)	1 Strong Buy rating(s)	2.83

Corcept Therapeutics has a net margin of 6.14% compared to Jazz Pharmaceuticals' net margin of 0.66%. Jazz Pharmaceuticals' return on equity of 14.56% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Jazz Pharmaceuticals	0.66%	14.56%	5.25%

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 89.1% of Jazz Pharmaceuticals shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 4.3% of Jazz Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Corcept Therapeutics has higher earnings, but lower revenue than Jazz Pharmaceuticals. Jazz Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	8.05	$99.65M	$0.35	163.09
Jazz Pharmaceuticals	$4.27B	3.42	-$356.15M	-$0.02	N/A

Summary

Corcept Therapeutics beats Jazz Pharmaceuticals on 11 of the 15 factors compared between the two stocks.

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Supernus Pharmaceuticals (NASDAQ:SUPN) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their profitability, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, valuation and risk.

Corcept Therapeutics has a net margin of 6.14% compared to Supernus Pharmaceuticals' net margin of -3.74%. Supernus Pharmaceuticals' return on equity of 13.07% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Supernus Pharmaceuticals	-3.74%	13.07%	9.66%
Corcept Therapeutics	6.14%	7.40%	5.76%

Supernus Pharmaceuticals has a beta of 0.57, suggesting that its share price is 43% less volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market.

Corcept Therapeutics has lower revenue, but higher earnings than Supernus Pharmaceuticals. Supernus Pharmaceuticals is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Supernus Pharmaceuticals	$776.83M	3.84	-$38.55M	-$0.51	N/A
Corcept Therapeutics	$761.41M	8.05	$99.65M	$0.35	163.09

In the previous week, Corcept Therapeutics had 5 more articles in the media than Supernus Pharmaceuticals. MarketBeat recorded 8 mentions for Corcept Therapeutics and 3 mentions for Supernus Pharmaceuticals. Supernus Pharmaceuticals' average media sentiment score of 0.83 beat Corcept Therapeutics' score of 0.72 indicating that Supernus Pharmaceuticals is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Supernus Pharmaceuticals	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Corcept Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

93.6% of Corcept Therapeutics shares are owned by institutional investors. 8.8% of Supernus Pharmaceuticals shares are owned by insiders. Comparatively, 20.7% of Corcept Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Supernus Pharmaceuticals presently has a consensus target price of $62.17, suggesting a potential upside of 21.04%. Corcept Therapeutics has a consensus target price of $70.83, suggesting a potential upside of 24.09%. Given Corcept Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Corcept Therapeutics is more favorable than Supernus Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Supernus Pharmaceuticals	1 Sell rating(s)	2 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.43
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Corcept Therapeutics beats Supernus Pharmaceuticals on 11 of the 16 factors compared between the two stocks.

How does Corcept Therapeutics compare to Nektar Therapeutics?

Nektar Therapeutics (NASDAQ:NKTR) and Corcept Therapeutics (NASDAQ:CORT) are both mid-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their valuation, earnings, analyst recommendations, media sentiment, institutional ownership, dividends, risk and profitability.

In the previous week, Nektar Therapeutics had 19 more articles in the media than Corcept Therapeutics. MarketBeat recorded 27 mentions for Nektar Therapeutics and 8 mentions for Corcept Therapeutics. Corcept Therapeutics' average media sentiment score of 0.72 beat Nektar Therapeutics' score of 0.43 indicating that Corcept Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Nektar Therapeutics	1 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral
Corcept Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Nektar Therapeutics has a beta of 1.24, meaning that its stock price is 24% more volatile than the broader market. Comparatively, Corcept Therapeutics has a beta of 0.36, meaning that its stock price is 64% less volatile than the broader market.

Corcept Therapeutics has higher revenue and earnings than Nektar Therapeutics. Nektar Therapeutics is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Nektar Therapeutics	$55.23M	46.47	-$164.08M	-$8.42	N/A
Corcept Therapeutics	$761.41M	8.05	$99.65M	$0.35	163.09

75.9% of Nektar Therapeutics shares are held by institutional investors. Comparatively, 93.6% of Corcept Therapeutics shares are held by institutional investors. 2.5% of Nektar Therapeutics shares are held by company insiders. Comparatively, 20.7% of Corcept Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Corcept Therapeutics has a net margin of 6.14% compared to Nektar Therapeutics' net margin of -284.18%. Corcept Therapeutics' return on equity of 7.40% beat Nektar Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Nektar Therapeutics	-284.18%	-85.40%	-39.99%
Corcept Therapeutics	6.14%	7.40%	5.76%

Nektar Therapeutics presently has a consensus target price of $149.63, suggesting a potential upside of 96.98%. Corcept Therapeutics has a consensus target price of $70.83, suggesting a potential upside of 24.09%. Given Nektar Therapeutics' higher possible upside, equities research analysts plainly believe Nektar Therapeutics is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Nektar Therapeutics	1 Sell rating(s)	1 Hold rating(s)	9 Buy rating(s)	0 Strong Buy rating(s)	2.73
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75

Summary

Corcept Therapeutics beats Nektar Therapeutics on 12 of the 17 factors compared between the two stocks.

How does Corcept Therapeutics compare to Perrigo?

Corcept Therapeutics (NASDAQ:CORT) and Perrigo (NYSE:PRGO) are both medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their earnings, risk, analyst recommendations, dividends, valuation, profitability, media sentiment and institutional ownership.

Corcept Therapeutics has a net margin of 6.14% compared to Perrigo's net margin of -43.50%. Perrigo's return on equity of 9.96% beat Corcept Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Corcept Therapeutics	6.14%	7.40%	5.76%
Perrigo	-43.50%	9.96%	3.90%

Corcept Therapeutics has a beta of 0.36, suggesting that its share price is 64% less volatile than the broader market. Comparatively, Perrigo has a beta of 0.52, suggesting that its share price is 48% less volatile than the broader market.

In the previous week, Corcept Therapeutics had 6 more articles in the media than Perrigo. MarketBeat recorded 8 mentions for Corcept Therapeutics and 2 mentions for Perrigo. Corcept Therapeutics' average media sentiment score of 0.72 beat Perrigo's score of 0.51 indicating that Corcept Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Corcept Therapeutics	4 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive
Perrigo	1 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive

Corcept Therapeutics presently has a consensus price target of $70.83, indicating a potential upside of 24.09%. Perrigo has a consensus price target of $19.33, indicating a potential upside of 76.80%. Given Perrigo's higher probable upside, analysts clearly believe Perrigo is more favorable than Corcept Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Corcept Therapeutics	0 Sell rating(s)	3 Hold rating(s)	4 Buy rating(s)	1 Strong Buy rating(s)	2.75
Perrigo	1 Sell rating(s)	4 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00

Corcept Therapeutics has higher earnings, but lower revenue than Perrigo. Perrigo is trading at a lower price-to-earnings ratio than Corcept Therapeutics, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Corcept Therapeutics	$761.41M	8.05	$99.65M	$0.35	163.09
Perrigo	$4.25B	0.36	-$1.43B	-$13.10	N/A

93.6% of Corcept Therapeutics shares are held by institutional investors. Comparatively, 95.9% of Perrigo shares are held by institutional investors. 20.7% of Corcept Therapeutics shares are held by company insiders. Comparatively, 0.4% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company is poised for long-term growth.

Summary

Corcept Therapeutics beats Perrigo on 12 of the 17 factors compared between the two stocks.

Get Corcept Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding CORT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

CORT vs. The Competition

Export

Metric	Corcept Therapeutics	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.49B	$3.04B	$6.30B	$12.20B
Dividend Yield	N/A	1.96%	2.79%	5.30%
P/E Ratio	163.09	18.86	21.03	25.58
Price / Sales	8.05	289.31	552.98	78.84
Price / Cash	56.67	56.53	42.94	55.34
Price / Book	9.61	4.35	9.82	6.66
Net Income	$99.65M	$72.19M	$3.55B	$333.63M
7 Day Performance	11.81%	-1.05%	-0.53%	-0.11%
1 Month Performance	30.68%	-0.02%	1.20%	3.94%
1 Year Performance	-19.42%	46.31%	41.23%	36.07%

Corcept Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
CORT Corcept Therapeutics	4.1609 of 5 stars	$57.08 +11.6%	$70.83 +24.1%	-19.1%	$5.49B	$761.41M	163.09	300	Positive News Analyst Upgrade Gap Up High Trading Volume
ANVS Annovis Bio	1.9889 of 5 stars	$2.40 +5.5%	$13.50 +463.7%	+30.0%	$78.65M	N/A	N/A	3	Upcoming Earnings
JAZZ Jazz Pharmaceuticals	2.3758 of 5 stars	$228.57 +7.7%	$229.38 +0.4%	+125.8%	$13.32B	$4.44B	N/A	2,890	High Trading Volume
SUPN Supernus Pharmaceuticals	2.7832 of 5 stars	$51.45 +4.6%	$62.17 +20.8%	+59.1%	$2.85B	$718.95M	N/A	580	Gap Up High Trading Volume
NKTR Nektar Therapeutics	2.8553 of 5 stars	$85.09 +1.1%	$140.63 +65.3%	+613.2%	$2.84B	$55.23M	N/A	220	Trending News Earnings Report Analyst Forecast Analyst Revision

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:CORT) was last updated on 5/14/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, JAZZ, SUPN, NKTR, and PRGO

How does Corcept Therapeutics compare to Annovis Bio?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Summary

How does Corcept Therapeutics compare to Nektar Therapeutics?

Summary

How does Corcept Therapeutics compare to Perrigo?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Corcept Therapeutics (CORT) Competitors

CORT vs. ANVS, JAZZ, SUPN, NKTR, and PRGO

How does Corcept Therapeutics compare to Annovis Bio?

Which has more volatility and risk, CORT or ANVS?

Which has better earnings and valuation, CORT or ANVS?

Do analysts recommend CORT or ANVS?

Does the media prefer CORT or ANVS?

Do institutionals and insiders hold more shares of CORT or ANVS?

Is CORT or ANVS more profitable?

Summary

How does Corcept Therapeutics compare to Jazz Pharmaceuticals?

Which has more volatility and risk, CORT or JAZZ?

Does the media prefer CORT or JAZZ?

Do analysts recommend CORT or JAZZ?

Is CORT or JAZZ more profitable?

Do institutionals and insiders hold more shares of CORT or JAZZ?

Which has better earnings and valuation, CORT or JAZZ?

Summary

How does Corcept Therapeutics compare to Supernus Pharmaceuticals?

Is SUPN or CORT more profitable?

Which has more risk and volatility, SUPN or CORT?

Which has preferable valuation & earnings, SUPN or CORT?

Does the media refer more to SUPN or CORT?

Do institutionals & insiders believe in SUPN or CORT?

Do analysts rate SUPN or CORT?

Summary

How does Corcept Therapeutics compare to Nektar Therapeutics?

Does the media refer more to NKTR or CORT?

Which has more volatility & risk, NKTR or CORT?

Which has better valuation and earnings, NKTR or CORT?

Do insiders and institutionals believe in NKTR or CORT?

Is NKTR or CORT more profitable?

Do analysts rate NKTR or CORT?

Summary

How does Corcept Therapeutics compare to Perrigo?

Is CORT or PRGO more profitable?

Which has more volatility and risk, CORT or PRGO?

Does the media refer more to CORT or PRGO?

Do analysts recommend CORT or PRGO?

Which has stronger valuation & earnings, CORT or PRGO?

Do insiders and institutionals have more ownership in CORT or PRGO?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

CORT vs. The Competition

Corcept Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools